SCHEDULE: Amneal Pharma Insider Pledges 13.2M Shares for Loan

Chintu Patel, a significant shareholder of Amneal Pharmaceuticals, Inc., has pledged over 13.2 million Class A Common Stock shares as collateral for a margin loan agreement with Citibank, N.A.

Summary

• Chintu Patel, a reporting person, updated his Schedule 13D filing for Amneal Pharmaceuticals, Inc.
• My beneficial ownership of Class A Common Stock is 25,910,032 shares, representing 8.2% of the class, based on 314,079,309 shares outstanding as of August 7, 2025.
• On October 3, 2025, a trust controlled by me contributed 13,257,287 shares of Class A Common Stock to Shivkan Holdings X, LLC, an entity solely owned by the trust.
• Shivkan Holdings X, LLC subsequently entered into a Margin Loan Agreement with Citibank, N.A., pledging these 13,257,287 shares as collateral.
• The obligations under the Margin Loan Agreement mature on April 5, 2027.
• Amneal Pharmaceuticals, Inc. also entered into an Issuer Letter Agreement with Citibank, N.A. to facilitate the exercise of rights by Citibank upon certain events.
• The pledged shares are restricted securities under Rule 144 and are held in book-entry form at DTC.

Sentiment

Score: 4

Explanation: The pledging of a significant portion of an insider's shares for a margin loan introduces potential downside risk due to possible forced selling, which could negatively impact the stock price. While not inherently negative, it adds a layer of complexity and potential volatility. The company's confirmation of compliance with policies is a minor positive, but the overall sentiment leans cautious due to the inherent risks of margin loans on large insider holdings.

Positives

• Amneal Pharmaceuticals, Inc. confirmed that the transactions do not violate its trading or corporate policies, organizational documents, or existing agreements with the borrower.
• Amneal Pharmaceuticals, Inc. confirmed the pledged shares are validly issued, fully paid, and non-assessable, and not subject to preemptive or similar rights or other Transfer Restrictions beyond Permitted Transfer Restrictions.

Negatives

• A significant portion of a key insider's holdings (13,257,287 shares, approximately 51% of Chintu Patel's total beneficial ownership) is now pledged as collateral for a margin loan.
• Upon certain customary events of default, Citibank, N.A. may foreclose on and dispose of the collateral, potentially leading to forced selling of a large block of shares.
• The sale of such a large block of shares could result in proceeds significantly less than market value if sold at different times or in different manners, and could put downward pressure on the stock price.
• The Pledgor (Shivkan) waives the right to require marshaling of collateral, giving Citibank discretion in realizing upon the collateral.

Risks

• Forced Selling Risk: If an event of default occurs under the Margin Loan Agreement, Citibank, N.A. has the right to foreclose on and sell the 13,257,287 pledged shares. Such a sale could be at prices and terms less favorable than a public sale without restrictions, potentially impacting the stock price.
• Market Impact Risk: The sale of a large block of shares (13,257,287 shares, representing 4.2% of outstanding Class A Common Stock) could create significant downward pressure on the company's stock price, especially if executed quickly or without seeking strategic buyers.
• Ownership Limitation Risk: The Margin Loan Agreement includes an "Ownership Provision" limiting Citibank's beneficial ownership to 9.0% of total outstanding shares or a lower threshold if it triggers reporting/registration obligations or adverse effects under "Applicable Restrictions." This could complicate or delay the disposition of collateral.
• Liquidity Risk for Pledgor: The Pledgor (Shivkan) acknowledges that the number of pledged shares may exceed the volume that can be sold quickly on the Exchange, and the Collateral Agent is not obligated to sell shares via a "dribble out" program.
• Reputational Risk: The pledging of a significant portion of an insider's shares for a margin loan can sometimes be perceived negatively by the market, raising questions about the insider's personal liquidity or confidence in the company's future.

Future Outlook

This filing does not contain explicit forward-looking statements or guidance from the company, but rather details a past transaction (October 3, 2025) and its implications. The margin loan matures on April 5, 2027.

Industry Context

Margin loans by insiders are a common, albeit sometimes scrutinized, method for individuals to gain liquidity against their equity holdings without selling shares. This transaction is specific to an individual's financial planning and does not directly reflect broader industry trends, though it highlights the use of equity as collateral in the financial sector.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing to allow for a direct comparison to global benchmarks. The transaction is a standard margin loan arrangement.

Corporate Governance

Related Party Transactions

• Chintu Patel, a reporting person, controls the trust that owns Shivkan Holdings X, LLC, which entered into the Margin Loan Agreement. This constitutes a transaction involving a significant insider.

Stakeholder Impact

• Shareholders: Potential for increased stock price volatility and downward pressure if the pledged shares are subject to forced selling due to a margin call or default.
• Company (Amneal Pharmaceuticals, Inc.): The company is involved through the Issuer Letter Agreement, committing to cooperate in the event of a forced sale, which could indirectly affect its market perception.
• Chintu Patel (Reporting Person): Gains liquidity from the margin loan but faces the risk of losing a significant portion of his equity stake if the loan defaults.

Next Steps

• The obligations under the Margin Loan Agreement mature on April 5, 2027.
• Upon an acceleration of the Total Accrued Loan Amount, Citibank, N.A. may exercise its rights to foreclose on and dispose of the pledged collateral.
• The Pledgor is obligated to cooperate with the Collateral Agent in any transfer of pledged shares made pursuant to the exercise of remedies.

Key Dates

Recommendation

The filing details a significant insider pledging a substantial portion of their shares for a margin loan. While this provides liquidity to the insider, it introduces a notable risk of forced selling if the loan defaults or a margin call occurs, which could put downward pressure on the stock price. The company's involvement through the Issuer Letter Agreement acknowledges this risk. Given the potential for increased volatility and the absence of new positive operational or financial news, a 'hold' recommendation is appropriate, advising investors to monitor the situation closely without taking new positions based solely on this filing.

Keywords

Amneal Pharmaceuticals, Chintu Patel, Schedule 13D, Margin Loan, Share Pledge, Beneficial Ownership, SEC Filing, Citibank, Corporate Governance, Risk Management, Equity Financing